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 
Abstract— A novel cardiac health device technique 
development for reliable, non-invasive and cost-effective heart 
screening in preventive cardiovascular healthcare is presented. 
In particular, identification of apparently healthy individuals 
involved in sports activities (particularly in the young, age < 35 
years) who may be at-risk of sudden-cardiac-death (SCD) is 
mainly focused here. Nevertheless, the same device technique 
may be prospectively extended for detecting cardiovascular 
abnormalities in children and adolescents with type1-diabetes, 
and also in detecting patients with Brugada syndrome. The 
device system has been aimed to provide a single figure 
diagnostic output, thus, not requiring highly-skilled medical 
personnel. The principles of the required ECG-waveform 
analysis algorithm have been reported in previous clinical 
studies. A prototype system platform design that will enable 
low-cost, portability and key user-friendly characteristics was 
implemented and in-vitro tested. Real-time firmware integrity 
and cardiac fitness detection algorithm performed reliably with 
an in-vitro positive SCD ECG-waveform modelling technique. 
I. INTRODUCTION 
      Sudden cardiac death (SCD) is a major health problem in 
Europe. While there are difficulties in estimating the exact 
incidence, in the Maastricht study that showed that during 
the 1990s in the Netherlands, 45% of SCD sufferers had no 
known history of cardiac disease and 40% had low or 
medium risk profiles following a heart attack [1]. It would 
be a significant advance if a method was devised capable of 
rapidly identifying a greater proportion of at risk individuals. 
An innovative approach could be by embedding within the 
related device technology the expertise required for the 
novel method. In this way, clinician training necessary for 
handling and interpreting new health devices using advanced 
concepts, can be minimised or not required at all. Thus 
benefits offered by improved, but sophisticated screening 
techniques are facilitated more quickly and efficiently into 
medical practice, leading to significant reduction on the 
frequency of SCD [2, 3]. Therefore, we aim to provide a 
medical device technology that is user friendly, portable, and 
cost-effective for cardiac screening using non-invasive ECG 
complex waveform analysis to achieve the required 
reliability of the cardiac risk screening procedure. The 
proposed ECG waveform fitness check (ECGWFC) device, 
is targeted to be operator independent. The device will just 
provide a single measurement figure (a dimensionless 
number) result output per person being checked. Therefore, 
the number of people being heart screened can be increased 
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only by increasing the number of ECGWFC units and the 
number of unspecialised clinicians, such as nurses or 
paramedics, who could be easily trained for operating the 
ECGWFC device and placing the required ECG electrodes 
(only 7 electrodes). Therefore, increasing the feasibility of 
the screening programme and reducing its operational costs.  
II. METHODS 
The key medical technology involved in the heart fitness 
check device comprises a technique of analysis of 
ventricular late potentials (VLP) measurements in a high-
resolution electrocardiographic recording using a unique 
ECG signal averaging (SAECG) process, named SFP (single 
fiducial point) [4]. SAECG improves the signal-to-noise 
ratio of a surface ECG, permitting the identification of VLP, 
which are low-amplitude (microvolt level) signals at the end 
of the ventricular activity [3]. A particular especial algorithm 
for VLP analysis quantifies a parameter related to the 
complexity of VLP waveforms in the 3D voltage space as 
the indicator for risk assessment (δLP) [5]. This is done by 
computing the fractal dimension of the 3D VLP curve drawn 
in a high definition voltage scale (in microvolts); the voltage 
curve being measured on three orthogonal (X,Y and Z) ECG 
signal components [6]. Several clinical studies have 
confirmed that a fractal dimension above 1.3, can be selected 
as the threshold value indicating risk of SCD in the subject 
being checked for heart fitness [5]. The reported standard 
deviation (σ) of δLP in the at-risk groups being about 0.08, 
and in the non at-risk groups being about 0.06, with 
difference between means ranging about twice those values 
(µ1 - µ2 ≈ 2σ). The fractal dimension quantification 
parameter δLP may be provided as a numerical display, or 
just as a simple SCD risk warning lamp (green/red) on the 
device, depending on whether the value of δLP is 
below/above a threshold value (e.g., a value of 1.3)[5].  
A. ECGWFC System Implementation 
     A real-time ECGWFC device system was implemented 
for VLP isolation and δLP analysis.  It is integrated by two 
main components: the hardware and the software 
subsystems.  The hardware subsystem includes rechargeable 
battery power supply, 3-channel low-noise ECG 
amplification, analogue signal conditioning, analogue to 
digital converters (ADC), embedded ECG processing opto-
isolation and interface chipset, and the portable PC (laptop) 
subsystem. The orthogonal bipolar XYZ lead system was 
adopted for recording the ECG signals [2]. 
As described for previous in-house high-resolution ECG 
acquisition system [6], the overall gain was set to 2000.  
Analogue signal conditioning was implemented by 1st order, 
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3Hz high-pass filtering at the front-end instrumentation 
amplifier, and low-pass filtering by an antialiasing 5th order 
filter at 360Hz.  Thus, the 3-channel front-end analogue 
ECG acquisition stage had a bandwidth from 3 up to 360Hz. 
Digitisation was carried out at 2 kHz sampling frequency 
and at 16-bit resolution (ADC).  
A micro-controller based firmware implemented the 
signal processing that enabled a highly accurate real-time 
alignment reference in the QRS complex for signal 
averaging (SAECG).  The Single-Fiducial-Point (SFP) 
alignment technique algorithm [4] was coded to carry out 
this real-time task. Thus, the X, Y and Z ECG channels data 
plus a QRS alignment reference bit data were output to the 
portable PC/laptop via the USB communication port. A 
LabView application code was implemented in the PC 
subsystem to provide the operator interface console, and to 
perform some required high level computational processes. 
SAECG and VLP Isolation 
The micro-controller embedded SFP alignment technique 
facilitated the real-time computation of the three SAECG 
frames; one for each of the orthogonal leads (X, Y, Z). In 
this process, the reference lead and the number of averaged 
beats were manually selected by the operator.  Then, 
conventional digital high-pass filtering at 40 Hz was 
implemented to generate the standard filtered SAECG 
frames for conventional VLP analysis (bi-directional, 4th 
order Butterworth high-pass digital filtering) on each lead: 
FX, FY and FZ [7]. 
VLP isolation was implemented as in previous works [6]. 
For this, first the XVLP, YVLP and ZVLP vector components are 
defined based on start and end timing marks obtained from 
the combined vector magnitude array A from the above 
filtered SAECG frames of each orthogonal lead, as defined 
in equation (1). 
 
𝑨 = √𝐹𝑋2 + 𝐹𝑌2 + 𝐹𝑍2                (1) 
 
     In the computed vector magnitude array A, the end timing 
mark (tend) of VLP activity was located at the moment when 
the of values in A becomes three times the background noise 
level in the ST segment region of the SAECG; and the start 
timing mark (tstart) was located when the values in A become 
greater than 40µV, in reverse time sequence move from the 
tend mark. In this process, values of A are averaged in a 10 
ms window, in 5 ms steps towards the QRS complex region.  
Then, the segments of each orthogonal filtered SAECG 
(FX, FY and FZ), delimited by the two time marks (tend, tstart), 
define the XVLP, YVLP and ZVLP vectors respectively, that is, 
the isolated VLP activity in each orthogonal lead. 
B. Computation of the δLP parameter 
Following the VLP demarcation process and the 
definition of vectors XVLP, YVLP and ZVLP, numerically 
scaled in microvolts, two important quantities are calculated 
in the 3D attractor constructed from these orthogonal filtered 
VLP components in the microvoltage space, in order to 
calculate the δLP parameter of VLP activity, which is used to 
detect patients that are at risk of SCD.  In our proposed 
method, we estimated the fractal dimension of the above 
attractor, according to Mandelbrot estimation formula: 
 
𝛿𝐿𝑃 ≈
𝑙𝑜𝑔(𝐶)
𝑙𝑜𝑔(𝚽)
                               (2) 
 
     In this formula, C would be the total length of the 
attractor’s 3D trajectory, and 𝚽 would be the spherical 
maximum possible diameter of the VLP attractor.  
Parameters C and Φ are therefore measured in μV units for 
properly computing the δLP parameter.  The value of C was 
calculated using the following summatory expression: 
 
𝐶 =  ∑ √(𝐹𝑋(𝑖) − 𝐹𝑋(𝑖 − 1))
2
+ (𝐹𝑌(𝑖) − 𝐹𝑌(𝑖 − 1))
2
+ (𝐹𝑍(𝑖) − 𝐹𝑍(𝑖 − 1))
2
𝑖=𝐾
𝑖=2
 
 
 (3) 
 
 
    In where K is the number of sampling periods in the 
delimited VLP attractor time interval given by: T = (tend - 
tstart), that is, the number of samples taken by the digitisation 
process in the interval T.  The determination of parameter Φ 
is computationally more intensive, but not complicated. For 
every pair of points in the 3D VLP attractor, the respective 
distance between them is computed using equation (4), and 
each calculated value used to populate the elements of the 
distance matrix Φmn defined in (5); then the maximum 
element value in Φmn yields the value of parameter Φ. 
 
 
 
𝛷𝑚𝑛 =  √(𝐹𝑋(𝑚) − 𝐹𝑋(𝑛))
2
+ (𝐹𝑌(𝑚) − 𝐹𝑌(𝑛))
2
+ (𝐹𝑍(𝑚) − 𝐹𝑍(𝑛))
2
 
(4) 
    
 
𝚽 = Max (𝛷𝑚𝑛)                       (5) 
 
      Because the distance matrix Φmn is symmetric, due to the 
square functions in the eq. (4), and zero diagonal elements 
resulting when m= n, only half of Φmn elements need to be 
calculated using eq. (4) to find the value of parameter Φ. 
Finally, as indicated above, our previous studies have 
suggested that a value above 1.3 of parameter δLP would be a 
reliable indication of a positive case of SCD risk. 
 
C. ECGWFC  System Performance Evaluation 
    A preliminary bench based assessment of the ECGWFC 
device system was implemented. For this, a 60 ms width 
QRS pulse model generated at a rate of 80 bpm, and of about 
1mV amplitude, was used as a modelled ECG signal, input 
into channel X, as the averaging reference lead. Because the 
WCGWFC device ECG amplifiers operate with a band-pass 
filtering from 3 to 360Hz, our modelled QRS signal is 
transformed into the biphasic pulse shown in Figure 1. 
 
D.1  Noise Immunity 
   Spectral degradation upon the SAECG due to noise 
interference effect on the SFP (Single-Fiducial-Point) 
alignment technique was assessed by means of the modelled 
ECG and deducing the standard deviation (SD) of alignment 
error (jitter), as a result of added noise into the modelled 
ECG signal input into the X channel of our ECGWFC 
device under bench test.  Thus, noise immunity of the adopted  
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Figure 1.  Synthetic QRS signal model. 
 
 
SAECG processing technique, under increasing noisy 
conditions was assessed under controlled adverse situations 
that results into spectral degradation of the SAECG process. 
For this, a noiseless (uncontaminated) modelled ECG signal 
was simultaneously fed into the Y or Z channels, while the 
controlled noisy ECG model signal was fed into the selected 
reference channel X. The types of simulated added noise 
were EMG and 50 Hz mains interference. The embedded 
SFP algorithm attempts to generate the beat alignment 
timing mark, but with a corresponding noise effect error. 
The latter error in every beat is measured with respect to any 
of the noiseless input channels (Y or Z), carrying the 
information of the true moment of the QRS pulse position. 
Thus, by means of a simple noise immunity assessment 
algorithm, vectors of beat alignment errors (jitter) were 
generated for each controlled type and rms noise level 
condition of test. The assessment algorithm also computed 
the SD value of each jitter vector case. For the ECGWFC 
device operating sampling frequency of 2 kHz, a jitter vector 
SD value below 0.5 ms, was considered as good noise 
immunity, and with negligible spectral degradation effects in 
the SAECG process.  
 
D.2   ECG Denoising Performance 
    Assessment of the ECGWFC device required ECG 
denoising functionality was implemented in a controlled 
bench testing method, using the two types of simulated 
noises used for the noise immunity assessment: simulated 
EMG (band limited Gaussian noise) and 50 Hz interference 
(sinusoidal). In a similar manner, the modelled ECG signal 
was corrupted with seven stepped up noise levels and fed 
into the selected reference channel X of the ECGWFC 
device. Then, ECG denoising performance at each level and 
type of added noise was assessed by measuring progressive 
noise reduction by the SAECG process at 7 stages of 
increasing number of averaged beats, from 1 to 400. The 
expected performance profile for Gaussian type noise 
(simulated EMG), is a noise reduction that is inversely 
proportional to the square root of the number of averaged 
beats. 
 
D.3   In-vitro δLP Measurement Performance 
   The ECGWFC device was tested in several in-house 
healthy volunteers (N = 5). Thus, VLP activity in these small 
sample healthy cases was measured by the δLP parameter 
output by the ECGWFC device, in order to confirm the 
expected values of δLP characteristic in healthy subject cases. 
To emulate high VLP activity conditions in-vitro, ECG 
synchronised 3D model VLP signal was analogically 
generated using a filters bank network.  Therefore, the 
objective of the proposed δLP measurement assessment 
method was to provide in-vitro SCD positive ECG 
waveforms presenting rather complex 3D, VLP signal 
components at the input of the ECGWFC device under test. 
The 3D model VLP signal may also consist of three different 
bipolar wavelet pulses or resonant waveforms at natural 
frequencies ranging from 40 Hz to 120 Hz. A range of δLP 
values, at abnormal levels between 1.32 and 1.38 (see Figure 
2), was obtained by varying the amplitude of the ECG 
synchronised input pulse generation between 3V and 18V.  
 
 
 
Figure 2.   Modelled δLP values obtained as the ECG synchronised input 
pulse amplitude is adjusted between 3V and 18V. 
  
 
III. RESULTS 
 
A.   SAECG Spectral Degradation vs Noise 
 
   Figure 3 summarises de results obtained in the noise 
immunity bench assessment of the ECGWFC device, for 
both types of noise: Gaussian and 50 Hz. The SD value of 
each jitter (beat alignment error) vector case resulting from 
the SAECH process was measured by the above mentioned 
noise assessment algorithm. EMG noise was Gaussian at 300 
Hz bandwidth. With Gaussian type noise, values of 
theoretically deduced spectral deg r adat io n  ma y be  
estimated from alignment j it t er  SD values by the following  
  
 
 
Figure 3.   Beat alignment jitter resulting from added EMG and 50Hz noise 
levels to a clean signal. 
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relation BW = (0.13/(SD jitter)) [4]. For example, a 
Gaussian noise level of 70.1 µV (rms) can yield a 100 Hz 
BW limitation at the output of the SAECG process. Also, 
from Figure 3, it can be observed that a high 50Hz noise 
level case of 340µV(rms), can yield a jitter SD of 2.6 ms. A 
relatively high value compared to the 0.5 ms reference level 
explained above. 
     With EMG noise type, linear denoising trends of the 
square root of number of averaged beats (√N ), between final 
noise and initial noise levels, eq. (6), was confirmed for the 
implemented SAECG process in the ECGWFC device.  
  
(Initial noise level)  =  √𝑁  (Final noise level)            (6) 
 
 
B.   δLP Parameter Measurement Algorithm: In-vitro Test 
 
     To assess the functionality of the δLP parameter 
measuring algorithm implemented in the ECGWFC device, 
in-vitro control measurements were carried out in five in 
house healthy subjects within the research team (procedures 
approved by the Institutional Ethical Filter). The measured 
values of the δLP parameter in these healthy subjects (i.e., 
SCD -ve) were around 1.2 (mean value), and the standard 
deviation was of ±0.063. Thus, the values of δLP were all 
under 1.3; as expected for healthy subjects [4]. The 
conventional SAECG vector magnitude frame presentations 
were also constructed, and one of these is shown in Fig. 4(a).  
 
 
(a) 
 
 
(b) 
 
Figure 4.   Filtered SAECG vector magnitude frames obtained from a 
healthy subject case: (a) baseline SAECG recording, (b) SAECG recording 
with  added modelled VLP signal. 
 
      Then, after simultaneously adding the ECG synchronised 
VLP signal model, while the ECGWFC device recorded the 
body surface ECG signal again in the same healthy volunteer 
in Figure 4(a), the SAECG vector magnitude frame shown in 
Figure 4(b) was obtained. As the synthetic VLP model was 
of considerable complexity (to emulate SCD+ VLP activity), 
the measured value of the δLP parameter resulted to be 1.327.  
Thus, the value of δLP in this healthy subject increased from 
1.198 to 1.327 after the in-vitro implementation of a SCD+ 
ECG-waveform modelling technique, for testing the 
ECGWFC device measuring algorithm. 
IV. DISCUSSION AND CONCLUSIONS 
    The expertise dependency nature of conventional heart 
screening techniques, constitutes a major hindrance to their 
effective and ample adoption by clinicians [8]. The number 
of people being screened would be limited by the number of  
available specialised clinical staff in the screening 
programme. A cardiac screening technology that is accurate, 
portable and cost effective is important in providing a 
significant contribution to solving the problem. Here, we 
have implemented and in-vitro tested a solution technique, in 
which the required advanced expertise component is 
embedded within the system device. With this approach, the 
required clinician training is minimised, aiming to facilitate 
the benefits offered by solution technique into the clinical 
practice and significantly reducing the incidence of SCD in 
the population. Thus, an advancement for a novel medical 
technology that is user friendly, portable, and cost-effective 
for cardiac screening using non-invasive complex waveform 
analysis of the electrocardiogram, has been achieved. Such a 
novel device will require minimal or no specialised clinician 
training because of its embedded or integrated processing 
expertise, and also its simple patient grading output figure 
that is easy to interpret, as it could be a simple outcome lamp 
indicator. Thus, the flow of heart checked people in a 
screening day would depend mainly on the number of 
available ECGWFC units and the number of minimally 
trained healthcare personnel.  
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